NeuroKaire

NeuroKaire, formerly known as GenetikaPlus, is a precision psychiatry company that utilizes stem cell technology and artificial intelligence to personalize depression treatment. The company’s core technology, BrightKaire, involves a blood test where patient samples are reprogrammed into neuronal cells. These derived neurons are then exposed to various antidepressant medications in a laboratory setting to measure biological responses and predict the most effective treatment for the individual. By integrating these biological insights with genetic testing, the company aims to move beyond traditional trial-and-error prescribing methods.

This technology is designed to help clinicians reduce the time required to find effective antidepressant therapy, potentially minimizing unnecessary suffering, adverse side effects, and healthcare costs for patients with major depressive disorder. By providing biologically informed, data-driven reports, NeuroKaire aims to support more accurate, personalized treatment plans. Beyond its clinical diagnostic offerings, the company also works with pharmaceutical and biotechnology partners to leverage its platform for drug development, aiming to advance precision medicine across broader psychiatric and neurological conditions.